Nifty
:
15746.45
Sensex
:
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)
Nifty
Sensex
:
:
15746.45
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)

Wockhardt Ltd.

Pharmaceuticals & Drugs - Global

Rating :
41/99

BSE: 532300 | NSE: WOCKPHARMA

NSE BSE
527.80
27-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  555.90
  •  558.95
  •  521.30
  •  549.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  830661
  •  4436.07
  •  804.90
  •  254.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,849.24
  • N/A
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,889.18
  • N/A
  • 1.75

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.68%
  • 1.20%
  • 23.02%
  • FII
  • DII
  • Others
  • 2.74%
  • 0.02%
  • 3.34%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -4.44
  • -7.21
  • -12.75

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.64
  • 34.04
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.43
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.40
  • 1.91
  • 1.54

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 54.71
  • 79.70
  • 55.69

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
859.55
598.27
43.67%
631.96
686.93
-8.00%
764.02
748.60
2.06%
714.05
682.89
4.56%
Expenses
752.01
670.32
12.19%
712.22
680.92
4.60%
708.23
680.54
4.07%
697.35
670.04
4.08%
EBITDA
107.54
-72.05
-
-80.26
6.01
-
55.79
68.06
-18.03%
16.70
12.85
29.96%
EBIDTM
12.51%
-12.04%
-12.70%
0.87%
7.30%
9.09%
2.34%
1.88%
Other Income
14.90
7.95
87.42%
21.74
21.17
2.69%
103.13
42.26
144.04%
16.24
-0.20
-
Interest
64.10
73.70
-13.03%
54.63
61.44
-11.08%
59.85
78.73
-23.98%
60.90
64.66
-5.82%
Depreciation
64.34
55.96
14.97%
65.03
60.87
6.83%
67.88
56.22
20.74%
57.15
52.50
8.86%
PBT
-6.00
-336.24
-
-178.18
-95.13
-
31.19
-24.63
-
-85.11
-104.51
-
Tax
0.58
-110.66
-
-71.34
-143.86
-
-1.21
-17.12
-
-88.40
11.82
-
PAT
-6.58
-225.58
-
-106.84
48.73
-
32.40
-7.51
-
3.29
-116.33
-
PATM
-0.77%
-37.71%
-16.91%
7.09%
4.24%
-1.00%
0.46%
-17.04%
EPS
-1.15
68.63
-
-8.38
4.36
-
1.38
0.87
58.62%
0.32
-8.51
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
2,969.58
2,762.04
3,325.15
4,158.38
3,936.90
4,014.61
4,453.22
4,481.54
4,830.36
5,609.42
4,350.50
Net Sales Growth
9.31%
-16.93%
-20.04%
5.63%
-1.94%
-9.85%
-0.63%
-7.22%
-13.89%
28.94%
 
Cost Of Goods Sold
1,240.87
1,135.49
1,203.45
1,636.31
1,797.53
1,662.07
1,613.68
1,487.48
1,806.25
1,747.56
1,534.38
Gross Profit
1,728.71
1,626.55
2,121.70
2,522.07
2,139.37
2,352.54
2,839.54
2,994.06
3,024.11
3,861.86
2,816.12
GP Margin
58.21%
58.89%
63.81%
60.65%
54.34%
58.60%
63.76%
66.81%
62.61%
68.85%
64.73%
Total Expenditure
2,869.81
2,808.74
3,082.03
4,050.63
3,935.07
3,988.39
3,958.98
3,772.14
3,804.65
3,549.74
2,996.79
Power & Fuel Cost
-
82.37
85.41
93.30
77.80
110.10
113.99
101.40
92.17
97.08
80.38
% Of Sales
-
2.98%
2.57%
2.24%
1.98%
2.74%
2.56%
2.26%
1.91%
1.73%
1.85%
Employee Cost
-
762.95
743.33
800.38
937.06
966.51
950.77
868.87
768.63
655.90
572.91
% Of Sales
-
27.62%
22.35%
19.25%
23.80%
24.07%
21.35%
19.39%
15.91%
11.69%
13.17%
Manufacturing Exp.
-
151.85
120.90
153.76
135.27
179.40
228.07
236.03
240.85
180.06
115.03
% Of Sales
-
5.50%
3.64%
3.70%
3.44%
4.47%
5.12%
5.27%
4.99%
3.21%
2.64%
General & Admin Exp.
-
251.33
186.55
380.13
476.66
504.43
405.85
320.92
352.19
248.28
194.47
% Of Sales
-
9.10%
5.61%
9.14%
12.11%
12.56%
9.11%
7.16%
7.29%
4.43%
4.47%
Selling & Distn. Exp.
-
131.62
141.18
176.22
208.89
205.30
241.11
261.55
292.98
291.74
214.75
% Of Sales
-
4.77%
4.25%
4.24%
5.31%
5.11%
5.41%
5.84%
6.07%
5.20%
4.94%
Miscellaneous Exp.
-
293.13
601.21
810.53
301.86
360.58
405.51
495.89
251.58
329.12
214.75
% Of Sales
-
10.61%
18.08%
19.49%
7.67%
8.98%
9.11%
11.07%
5.21%
5.87%
6.55%
EBITDA
99.77
-46.70
243.12
107.75
1.83
26.22
494.24
709.40
1,025.71
2,059.68
1,353.71
EBITDA Margin
3.36%
-1.69%
7.31%
2.59%
0.05%
0.65%
11.10%
15.83%
21.23%
36.72%
31.12%
Other Income
156.01
129.81
60.08
21.02
120.23
100.83
66.10
66.55
38.40
54.00
25.34
Interest
239.48
249.08
275.74
265.14
255.49
225.27
128.96
55.21
83.35
215.37
269.02
Depreciation
254.40
246.02
224.14
163.95
149.53
148.93
141.91
145.40
139.92
122.14
115.07
PBT
-238.10
-411.99
-196.68
-300.32
-282.96
-247.15
289.47
575.34
840.84
1,776.17
994.96
Tax
-160.37
227.25
-153.29
-83.66
25.70
-21.11
37.88
162.65
47.88
258.21
221.74
Tax Rate
67.35%
24.81%
77.94%
27.86%
-4.01%
8.54%
13.09%
28.27%
5.38%
14.05%
42.54%
PAT
-77.73
686.06
-69.22
-194.53
-608.30
-195.72
250.08
404.91
840.72
1,579.48
299.45
PAT before Minority Interest
-86.71
688.60
-43.39
-216.66
-666.85
-226.04
251.59
412.69
842.79
1,579.48
299.45
Minority Interest
-8.98
-2.54
-25.83
22.13
58.55
30.32
-1.51
-7.78
-2.07
0.00
0.00
PAT Margin
-2.62%
24.84%
-2.08%
-4.68%
-15.45%
-4.88%
5.62%
9.04%
17.40%
28.16%
6.88%
PAT Growth
0.00%
-
-
-
-
-
-38.24%
-51.84%
-46.77%
427.46%
 
EPS
-7.02
61.92
-6.25
-17.56
-54.90
-17.66
22.57
36.54
75.88
142.55
27.03

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
3,376.76
2,671.67
2,674.80
2,852.15
3,336.71
3,775.12
3,715.35
3,581.47
2,704.18
1,471.02
Share Capital
55.39
55.37
55.34
55.32
55.27
55.25
353.59
353.43
353.34
816.09
Total Reserves
3,293.85
2,586.33
2,587.19
2,760.11
3,244.43
3,691.22
3,315.65
3,182.73
2,319.30
644.73
Non-Current Liabilities
496.72
1,194.85
1,702.75
2,088.89
3,151.38
1,893.49
1,872.46
1,161.18
1,520.80
2,891.88
Secured Loans
500.19
1,237.44
1,653.25
2,167.84
2,887.11
1,647.34
1,180.25
1,096.27
1,467.51
2,697.34
Unsecured Loans
2.66
3.46
238.22
5.27
303.16
273.26
4.59
6.03
7.64
9.05
Long Term Provisions
84.37
45.60
53.48
64.89
94.23
70.74
635.05
51.98
69.85
84.49
Current Liabilities
3,118.22
3,497.18
2,863.66
2,691.71
1,978.81
1,841.85
1,772.97
1,743.20
1,773.48
1,890.94
Trade Payables
577.97
895.27
840.24
601.78
533.81
637.69
552.56
557.79
634.15
540.80
Other Current Liabilities
1,345.49
1,579.80
1,353.09
1,548.13
690.13
621.23
844.44
947.70
789.96
978.38
Short Term Borrowings
1,066.11
903.86
561.71
437.09
662.80
550.03
348.28
210.20
182.00
260.80
Short Term Provisions
128.65
118.25
108.62
104.71
92.07
32.90
27.69
27.51
167.37
110.96
Total Liabilities
7,375.19
7,749.49
7,571.04
7,978.48
8,848.84
7,975.79
7,504.73
6,622.02
5,998.46
6,253.84
Net Block
3,343.12
3,502.29
3,057.93
2,887.96
2,772.55
2,808.70
2,122.74
2,294.63
1,989.60
2,571.34
Gross Block
5,655.58
6,703.28
6,112.89
5,772.29
5,456.40
4,377.01
4,552.96
4,642.81
4,295.75
4,211.60
Accumulated Depreciation
2,312.46
3,200.99
3,054.96
2,884.33
2,683.85
1,568.31
2,430.22
2,348.18
1,684.94
1,306.76
Non Current Assets
4,950.81
5,319.66
4,756.39
4,598.88
4,313.57
4,023.94
3,983.17
3,266.10
2,671.53
3,772.33
Capital Work in Progress
1,378.94
1,584.53
1,445.48
1,432.57
1,243.95
1,036.05
1,007.30
707.53
490.94
902.29
Non Current Investment
0.45
0.45
0.45
0.45
0.45
0.45
2.62
2.62
2.63
90.75
Long Term Loans & Adv.
227.36
230.63
252.37
277.90
296.62
178.74
845.68
235.86
183.35
207.95
Other Non Current Assets
0.94
1.76
0.16
0.00
0.00
0.00
4.83
25.46
5.01
0.00
Current Assets
2,424.38
2,429.83
2,814.65
3,379.60
4,535.27
3,951.85
3,521.56
3,355.92
3,326.93
2,481.51
Current Investments
0.00
0.00
0.00
213.25
562.27
0.00
338.72
573.98
0.00
0.00
Inventories
798.88
689.83
819.36
855.71
1,107.95
1,102.16
1,020.78
992.89
1,058.83
888.56
Sundry Debtors
917.65
1,242.69
1,273.90
962.45
1,034.45
1,111.42
741.43
481.04
958.46
758.69
Cash & Bank
291.79
268.46
448.65
1,082.25
1,603.61
1,478.11
1,234.55
1,125.80
1,096.06
699.99
Other Current Assets
416.06
56.64
20.18
8.31
226.99
260.16
186.08
182.21
213.58
134.27
Short Term Loans & Adv.
271.77
172.21
252.56
257.63
197.75
260.16
186.08
182.21
213.58
134.27
Net Current Assets
-693.84
-1,067.35
-49.01
687.89
2,556.46
2,110.00
1,748.59
1,612.72
1,553.45
590.57
Total Assets
7,375.19
7,749.49
7,571.04
7,978.48
8,848.84
7,975.79
7,504.73
6,622.02
5,998.46
6,253.84

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
-287.32
648.96
183.32
68.44
-269.47
71.61
354.96
1,476.29
1,532.40
1,343.83
PBT
915.85
-196.68
-300.32
-641.15
-247.15
357.01
575.34
890.67
1,860.20
576.72
Adjustment
-942.27
483.23
444.52
448.78
303.04
201.29
285.63
133.53
273.31
917.59
Changes in Working Capital
-143.59
379.58
80.29
278.33
-297.39
-402.76
-344.62
587.99
-266.99
-129.94
Cash after chg. in Working capital
-170.01
666.13
224.49
85.96
-241.50
155.54
516.35
1,612.19
1,866.52
1,364.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-117.31
-17.17
-41.17
-17.52
-27.97
-83.93
-161.39
-135.90
-334.12
-20.54
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,470.10
-155.53
94.57
630.24
-686.64
-818.19
-206.63
-851.62
1,085.37
-305.45
Net Fixed Assets
-199.82
-499.84
-39.00
-45.55
-166.75
-368.17
-299.87
-283.99
174.15
-181.64
Net Investments
0.00
0.00
-0.05
0.00
0.00
0.00
10.73
0.00
0.00
0.00
Others
1,669.92
344.31
133.62
675.79
-519.89
-450.02
82.51
-567.63
911.22
-123.81
Cash from Financing Activity
-1,170.82
-679.58
-776.45
-769.47
1,254.49
254.26
-75.65
-601.32
-2,245.75
-826.56
Net Cash Inflow / Outflow
11.96
-186.15
-498.56
-70.79
298.38
-492.32
72.68
23.35
372.02
211.82
Opening Cash & Equivalents
219.34
397.34
897.24
963.64
662.98
1,158.69
1,101.65
1,050.01
689.66
470.10
Closing Cash & Equivalent
232.25
219.34
397.34
897.24
963.64
664.64
1,158.69
1,101.65
1,050.01
689.66

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
302.33
238.55
238.75
254.47
298.51
339.05
306.20
294.97
216.65
63.91
ROA
9.11%
-0.57%
-2.79%
-7.93%
-2.69%
3.25%
6.09%
13.36%
25.78%
4.97%
ROE
22.99%
-1.64%
-7.94%
-21.81%
-6.42%
7.07%
12.49%
30.04%
102.78%
66.74%
ROCE
20.10%
1.32%
-0.56%
-5.47%
-0.31%
6.87%
11.25%
18.98%
43.10%
17.39%
Fixed Asset Turnover
0.45
0.52
0.70
0.70
0.82
1.00
0.98
1.08
1.32
1.05
Receivable days
142.74
138.12
98.15
92.57
97.55
75.93
49.71
54.33
55.81
57.17
Inventory Days
98.37
82.83
73.51
91.03
100.47
87.00
81.88
77.43
63.29
67.16
Payable days
99.63
129.66
86.65
67.29
64.08
64.54
63.71
65.00
65.49
65.74
Cash Conversion Cycle
141.48
91.29
85.01
116.31
133.94
98.39
67.88
66.75
53.61
58.58
Total Debt/Equity
0.70
1.22
1.28
1.33
1.26
0.71
0.55
0.54
0.77
2.25
Interest Cover
4.68
0.29
-0.13
-1.51
-0.10
3.24
11.42
11.69
9.53
2.94

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Wockhardt reports consolidated net loss of Rs 13 crore in Q1
    22nd Jul 2021, 14:33 PM

    Total consolidated income of the company increased by 42.06% at Rs 861.20 crore for Q1FY22

    Read More
  • Wockhardt incorporates new subsidiary
    5th Jul 2021, 10:02 AM

    The company has incorporated a new subsidiary namely Wockhardt Biologics on July 2, 2021

    Read More
  • Wockhardt gets nod to raise Rs 150 crore
    22nd May 2021, 11:56 AM

    The credit facilities committee of the board at its meeting held on May 21 has approved the raising of funds

    Read More
  • Wockhardt gets approval to raise funds upto Rs 150 crore
    22nd Apr 2021, 10:16 AM

    The company’s the Credit Facilities Committee of the Board of Directors at its meeting held on April 21, 2021 has approved the same

    Read More
  • Wockhardt planning to raise funds through NCDs
    19th Apr 2021, 11:23 AM

    The meeting of the Credit Facilities Committee of the Board of Directors of the Company is scheduled to be held on April 21, 2021, inter-alia, to consider and approve the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.